drugset / Trial / NCT02351739
Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Metastatic Urothelial Cancer
Timeline
- Start
- 2015-04
- Primary completion
- 2018-02
- Completion
- 2018-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acalabrutinib | Small molecule | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |